Eli Lilly Launches Innovative Drug 'Mounjaro' to Combat Obesity and Diabetes in India
Eli Lilly and Company (India) has launched 'Mounjaro,' a novel medication for obesity and type 2 diabetes, after receiving approval from the CDSCO. Mounjaro, an adjunct to diet and exercise, activates GIP and GLP-1 receptors and is aimed at improving weight management and glycemic control in adults.
Mounjaro, manufactured by Lilly, may have emerged as the newest and most effective treatment option after a victory over Novo Nordisk’s Ozempic in clinical trials. For some patients, injectables ...
Mounjaro (tirzepatide) is a brand-name injection prescribed for type 2 diabetes in adults. As with other drugs, Mounjaro can cause side effects, such as nausea, diarrhea, and appetite loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback